Dose Optimization Portion of the Phase 2 PRIMO Study in Relapsed or Refractory PTCL #ASH19 @sloan_kettering

Steven Horwitz, MD of @sloan_kettering discusses the phase 2 PRIMO study.

_______

Verastem, Inc. (Nasdaq:VSTM) (Verastem Oncology or the Company), a biopharmaceutical company focused on developing and commercializing medicines seeking to improve the survival and quality of life of cancer patients, today announced the presentation of key abstracts highlighting COPIKTRA®…

Read the full article here

Related Articles